Last reviewed · How we verify
NCT03945110
Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury
Phase 1, PHASE2 trial testing iAluRil® intravesical instillations in Spinal Cord Injuries in 10 participants. Completed in 18 March 2021.
22 September 2020
Quick facts
| Lead sponsor | The University of Western Australia |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 10 |
| Start date | 18 September 2019 |
| Primary completion | 22 September 2020 |
| Estimated completion | 18 March 2021 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- iAluRil® intravesical instillations
Conditions studied
- Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
Sponsor
The University of Western Australia
Who can join
Adults 18 to 70, any sex, with Spinal Cord Injuries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety and feasibility of administering glycosaminoglycan (GAG) therapy, iAluRil®, intravesically in individuals with acute spinal cord injury (SCI), commencing within the first ten days of injury, to prevent early urinary tract infections.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intravesical hyaluronic acid with chondroitin sulphate to prevent urinary tract infection after spinal cord injury.
King GK, Goodes LM, Hartshorn C, Thavaseelan J, et al · · 2023 · cited 7× · PMID 35792831 · DOI 10.1080/10790268.2022.2089816
Verify or expand the search:
- PubMed search for NCT03945110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Cord Injuries
Currently open trials in the same condition.
- NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
- NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
- NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
- NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
- NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting
Other The University of Western Australia trials
Trials by the same sponsor.
- NCT06951659 — Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours · recruiting
- NCT06571994 — The Plastic Exposure Reduction Transforms Health Trial · NA · completed
- NCT04322136 — AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion · NA · unknown
- NCT03163602 — Surgical Treatment of Peri-implantitis · NA · completed
- NCT03433664 — Carbon Dioxide Laser Treatment in Burn-related Scarring · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03945110 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Western Australia
- Last refreshed: 3 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03945110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing